BioLife Solutions, Qkine partner on cytokine distribution and CellSeal Connect packaging
- BioLife expands its CGT supply‑chain presence via a multi‑year agreement with Qkine.
- BioLife gains exclusive worldwide distribution for selected Qkine cytokines, broadening biologically active media beyond supplements.
- BioLife’s CellSeal Connect packaging enables closed‑system, automated CGT workflows, reducing manual handling and contamination risk.
BioLife forges distribution and packaging tie-up with Qkine
BioLife Solutions is expanding its presence in the cell and gene therapy (CGT) supply chain through a multi‑year agreement with Cambridge‑based Qkine, the companies announce from Bothell, Washington. Under the deal, BioLife receives exclusive worldwide distribution rights to certain Qkine cytokine and growth factor products for the CGT market and non‑exclusive rights to others, positioning BioLife to broaden its biologically active media offerings beyond current cell culture supplements. The multi‑year nature of the agreement signals both firms’ long‑term commitment to the growing CGT sector.
The collaboration extends beyond distribution to a process development and validation program that enables Qkine to package selected products using BioLife’s CellSeal® Connect vial system. BioLife says the CellSeal Connect format is designed for closed‑system and automated CGT workflows and aims to simplify integration into bioprocess operations, reducing manual handling and contamination risk during clinical and commercial manufacturing. The partnership therefore targets both supply chain scale-up and workflow automation as CGT developers move toward larger‑scale and more standardized production.
Company executives frame the deal as strategic alignment: Roderick de Greef, BioLife’s chairman and CEO, says the relationship complements BioLife’s existing cell culture supplement portfolio and advances its strategy to enter biologically active media components—an adjacent category the company views as fast‑growing and profitable. Qkine chief executive Dr. Robert Scoffin says combining Qkine’s high‑purity cytokines with BioLife’s distribution reach and customer relationships is intended to deliver greater customer value and help accelerate manufacture of next‑generation cell and gene therapies.
Market and partner background
Cytokines and growth factors play central roles in regulating and stimulating cell growth, activation and performance in CGT manufacturing, and third‑party research estimates put the current global cytokines market at about $500 million annually, growing at a mid‑teens compound annual rate to roughly $1 billion by 2030. Qkine focuses on high‑purity, bioactive growth factors and cytokines to support stem cell and regenerative medicine research, clinical translation and commercial‑scale manufacturing.
Operational implications
By securing exclusive distribution for selected Qkine products and collaborating on CellSeal Connect packaging, BioLife aims to deepen its position as a supplier of critical bioproduction tools and services that support automated, closed CGT workflows and the industry’s push toward scalable, standardized manufacturing.